50 Broadway
Westminster
SW1H 0RG
+44 20 7152 4080
+44 20 7152 4001
Tracy Weimar
ImmuPharma is one of the leading specialist drug development companies listed on AIM of the LSE. Our corporate strategy and business model differentiates us from many of their peers. They have UK, French and Swiss operations and have a formal research collaboration with Europe’s largest fundamental research organization in Europe, the Centre National de la Recherche Scientifique (CNRS). ImmuPharma has received to-date $45 million from a corporate deal with a US pharmaceutical company and a number of grants from French government organisations for three of our drug candidates. Their most advanced compound has recently been given the approval from the US FDA to enter phase III with a special protocol assessment and Fast Track designation.
Description | Report Date | Published |
---|---|---|
Annual Report 2012 | 31-12-2012 | 08-04-2013 |
Annual Report 2011 | 31-12-2011 | 26-03-2012 |
Annual Report 2010 | 31-12-2010 | 04-04-2011 |
Annual Report 2009 | 31-12-2009 | 17-05-2010 |
Annual Report 2008 | 31-12-2008 | 23-06-2009 |
Annual Report 2007 | 31-12-2007 | 07-05-2008 |
Annual Report 2006 | 31-12-2006 | 30-04-2007 |
Description | Report Date | Published |
---|
Description |
---|
RSS News Feed |
Investor Relations |
Site Map |
Home |
Press Releases |
Contacts |
Type | Dividend | Payment Date |
---|